Hi everyone,

I found this tiny tidbit buried in a newslink and find it encouraging...here's to hope:

Up at Oxford
Oxford Biomedica, the FTSE-listed biopharmaceutical firm, saw its shares rise nearly 6% to 23.25p after encouraging news in the development of its gene therapy treatment for Parkinson's disease. The aim of its ProSavin treatment is to introduce genes responsible for dopamine production into cells that populate the area of the brain that is dopamine deficient. Analysts at Panmure Gordon noted that a second patient has been "dosed" on ProSavin. "The importance of the second patient being dosed is that it comes a full month after the first patient, which implies that no issues were raised on safety," Panmure said, adding that the company remains "well capitalised". It repeated its buy recommendation on Oxford Biomedica and its 69p price target